Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe short answer is: the licensed titration schedule requires at least four weeks at each dose before any increase, so moving up after three weeks falls outside what the Mounjaro prescribing guidance supports. That four-week minimum isn't arbitrary — it reflects what the clinical trials, including SURMOUNT-1, published in the New England Journal of Medicine, used to establish both the medicine's safety profile and its effectiveness at each strength. Mounjaro is a prescription-only medicine, and any change to your titration timing is a decision made with your prescriber, not something to adjust independently.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The Mounjaro Summary of Product Characteristics, which you can review on the electronic Medicines Compendium (eMC), is explicit: treatment starts at 2.5 mg once weekly, and the dose is increased in 2.5 mg steps at intervals of at least four weeks. "At least" is doing real work in that sentence. It is a floor, not a target. Some people stay at a given dose for eight or twelve weeks because their body hasn't finished settling, or because their prescriber judges that another four weeks of consolidation will serve them better than a bump in strength.
The four-week rule emerged from how the SURMOUNT trials were designed. Participants moved through the dose ladder on roughly monthly steps, which gave researchers a consistent framework for measuring tolerability at each level. Borrowing a shorter interval wasn't studied, so there is simply no good evidence that three weeks produces equivalent outcomes, and the GI side-effect data suggests the dose-increase window exists partly to protect the gut from being overwhelmed.
If you are wondering whether your situation is different, the honest answer is that it might be, but that is precisely the kind of clinical judgement a prescriber needs to make having seen your full picture, not a general rule you can apply yourself. See the guidance on when to increase your Mounjaro dose for a fuller look at the factors your prescriber weighs up.
A lot of people assume that reaching the higher doses sooner will accelerate weight loss. It is a reasonable thing to think, and it is also the thing most likely to backfire. Tirzepatide's appetite-regulating effect builds over weeks as the medicine reaches steady state in your system. Pushing to a higher concentration before your body has adapted doesn't skip that process, it just means you are more likely to experience severe nausea or vomiting at a point when the benefit hasn't meaningfully increased yet.
The starter-dose period exists to let your gut accommodate the medicine, full stop. Skipping or compressing it is one of the clearest predictors of people stopping treatment early because side effects became unmanageable, which, from a weight-management perspective, is the worst outcome of all. Slower titration often means better long-term adherence, and adherence is what drives results. That is not a platitude; it is what the trial data show.
It is also worth noting that the 5 mg dose is itself a meaningful therapeutic step. Many people see significant progress at 5 mg and 7.5 mg without ever needing to reach the highest strengths. Racing to 15 mg is not the goal.
Before any increase is approved, a responsible prescriber reviews tolerability at your current dose. That means looking at whether GI side effects have settled, whether you have had any unusual symptoms, and whether your reported response suggests your system has genuinely adjusted. At nume, a GPhC-registered Independent Prescriber personally reviews your case before each repeat, it is a clinician reading your notes, not automated software making a call.
If three weeks have passed and you are feeling well, that is a good sign, but it is also a sign that the fourth week will pass without difficulty, making waiting the lower-risk path. If, on the other hand, you are still experiencing significant nausea at week three, that is useful clinical information suggesting you may need longer at the current dose, not a shorter wait before increasing. The reasons behind dose increases and what the prescriber is actually looking for are worth reading before your next review.
For broader context on how Mounjaro fits into a weight-management plan and what private treatment involves financially, the Mounjaro cost comparison page lays out what a legitimate prescription service includes. And if you want to understand the full picture of the medicine before your next appointment, the Mounjaro overview covers everything from mechanism to eligibility.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.